Product Pathways - Cell Cycle / Checkpoint
CDK9 (C12F7) Rabbit mAb #2316
|2316S||100 µl (10 western blots)||---||In Stock||---|
|2316P||40 µl (4 western blots)||---||In Stock||---|
|2316||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat, Hamster, Monkey, Bovine, Dog||Endogenous||42, 55||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin), IHC-F=Immunohistochemistry (Frozen), IF-IC=Immunofluorescence (Immunocytochemistry), F=Flow Cytometry
Specificity / Sensitivity
CDK9 (C12F7) Rabbit mAb detects endogenous levels of total CDK9 protein, both 42 kDa and 55 kDa isoforms.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CDK9.
Western blot analysis of extracts from various cell types using CDK9 (C12F7) Rabbit mAb.
Immunoprecipitation of CDK9 from HeLa cells using CDK9 (C12F7) Rabbit mAb. Western blot detection was performed using the same antibody. Lane 1 is 5% input.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using CDK9 (C12F7) Rabbit mAb in the presence of control peptide (left) or antigen specific peptide (right).
Immunohistochemical analysis of paraffin-embedded K7M2 mouse syngeneic tumor using CDK9 (C12F7) Rabbit mAb.
Immunohistochemical analysis of frozen SKOV-3 xenograft using CDK9 (C12F7) Rabbit mAb.
Flow cytometric analysis of Jurkat cells using CDK9 (C12F7) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).
P-TEFb is a general transcription factor that regulates transcription elongation through phosphorylation of the C-terminal tail domain (CTD) of RNA polymerase II (RNAP II). The P-TEFb complex composed of a catalytic subunit, CDK9, and its regulatory cyclin partner, which can be cyclin T1, T2a, T2b or K (reviewed in 1,2). P-TEFb is recruited by the HIV Tat protein to allow transcriptional elongation, and subsequent replication of the viral genome. Inhibition of P-TEFb function therefore has potential for HIV therapy.
CDK9 exists as two isoforms, an abundant 42 kDa isoform, and a less abundant 55 kDa isoform, which contains an amino-terminal extension (3). The two forms likely have distinct purposes based on differential expression during lymphocyte activation (4,5) and on their localization within the nucleus (5).
Cyclin dependent kinases (CDKs) are activated in part by cyclin binding and by phosphorylation of a conserved threonine in the T-loop domain. Phosphorylation of CDK9 at the T-loop Thr186 by an unidentified nuclear kinase may be important in P-TEFb activation (6) and regulation of HIV transcription (7). Acetylation of CDK9 at Lys44 affects its ability to phosphorylate the RNAPII CTD (8).
- Rice, A.P. and Herrmann, C.H. (2003) Curr HIV Res 1, 395-404.
- De Falco, G. and Giordano, A. Cancer Biol Ther 1, 342-7.
- Shore, S.M. et al. (2003) Gene 307, 175-82.
- Shore, S.M. et al. (2005) Gene 350, 51-8.
- Liu, H. and Herrmann, C.H. (2005) J Cell Physiol 203, 251-60.
- Chen, R. et al. (2004) J Biol Chem 279, 4153-60.
- Ammosova, T. et al. (2005) Retrovirology 2, 47.
- Fu, J. et al. (2007) Mol Cell Biol 27, 4641-51.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 2549 Phospho-CDK9 (Thr186) Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
- 8112 SignalStain® Antibody Diluent
- 8114 SignalStain® Boost IHC Detection Reagent (HRP, Rabbit)
- 9997 Tris Buffered Saline with Tween® 20 (TBST-10X)
- 5425 Normal Goat Serum
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
This antibody is developed, validated, and produced by CST using in part technology under license (granting certain rights including those under U.S. Patent No. 5,675,063) from Epitomics, Inc.